Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Gemini · PHAD

Other · developed by Revelation Biosciences

Phase 1/2 Most advanced trial (none active)

REVB Developer

1 Registered trials

What is Gemini?

Gemini is an investigational drug studied in Renal Insufficiency, Chronic, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4.

At a glance

Also known as: PHAD, Phosphorylated hexaacylated disaccharide
Drug type: Other
Therapy area: Renal & urology
Developer: Revelation Biosciences, Inc (REVB)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: A1O9D5VN5D

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06863467	Phase 1/2	Renal Insufficiency, Chronic	Completed	REVB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Kidney Disease stage3Chronic Kidney Disease stage4Renal Insufficiency, Chronic

Sources

ClinicalTrials.gov NCT06863467

Updated Oct 3, 2026. Something wrong or missing? Report it on the REVB page.

Follow REVB, the company behind Gemini

See REVB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REVB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z